Edgewise Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The Stifel 2022 Healthcare Conference will take place on November 16, 2022, at 3:00 pm ET, while the Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 8:30 am ET. Both presentations will be webcast live, with replay availability. Edgewise focuses on developing therapies for rare muscle disorders, notably pursuing its lead candidate, EDG-5506, in clinical trials.

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following upcoming investor conferences:

Stifel 2022 Healthcare Conference
Presentation: Wednesday, November 16, 2022, at 3:00 pm ET

Piper Sandler 34^th Annual Healthcare Conference
Presentation: Tuesday, November 29, 2022, at 8:30 am ET

The presentations will be webcast live; links for the webcasts can be found on the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne muscular dystrophy or Becker muscular dystrophy. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005318/en/

Investors & Media

Michael Carruthers

Chief Financial Officer

ir@edgewisetx.com

Source: Edgewise Therapeutics

FAQ

What presentations will Edgewise Therapeutics conduct at the investor conferences?

Edgewise Therapeutics will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 3:00 pm ET, and at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 8:30 am ET.

Where can I watch the Edgewise Therapeutics presentations?

The presentations by Edgewise Therapeutics will be webcast live, and links will be available on their events page.

What is EDG-5506 and its significance for Edgewise Therapeutics?

EDG-5506 is Edgewise Therapeutics' lead candidate, an orally administered small molecule myosin modulator in clinical trials for treating rare muscle disorders like Duchenne and Becker muscular dystrophy.

What is the focus of Edgewise Therapeutics as a biopharmaceutical company?

Edgewise Therapeutics focuses on developing therapies for rare neuromuscular and cardiac disorders with significant unmet medical needs.